These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22831980)

  • 1. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.
    Di Forti M; Iyegbe C; Sallis H; Kolliakou A; Falcone MA; Paparelli A; Sirianni M; La Cascia C; Stilo SA; Marques TR; Handley R; Mondelli V; Dazzan P; Pariante C; David AS; Morgan C; Powell J; Murray RM
    Biol Psychiatry; 2012 Nov; 72(10):811-6. PubMed ID: 22831980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.
    van Winkel R; van Beveren NJ; Simons C;
    Neuropsychopharmacology; 2011 Nov; 36(12):2529-37. PubMed ID: 21775978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?
    Hindocha C; Quattrone D; Freeman TP; Murray RM; Mondelli V; Breen G; Curtis C; Morgan CJA; Valerie Curran H; Di Forti M
    Transl Psychiatry; 2020 May; 10(1):143. PubMed ID: 32398646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabis and a lower BMI in psychosis: What is the role of AKT1?
    Liemburg EJ; Bruins J; van Beveren N; Islam MA; Alizadeh BZ;
    Schizophr Res; 2016 Oct; 176(2-3):95-99. PubMed ID: 27554198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosis.
    Trotta A; Iyegbe C; Yiend J; Dazzan P; David AS; Pariante C; Mondelli V; Colizzi M; Murray RM; Di Forti M; Fisher HL
    Schizophr Res; 2019 Mar; 205():51-57. PubMed ID: 29653893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.
    Morgan CJ; Freeman TP; Powell J; Curran HV
    Transl Psychiatry; 2016 Feb; 6(2):e738. PubMed ID: 26882038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms.
    Carvalho C; Vieira-Coelho MA
    Pharmacol Res; 2022 Jul; 181():106258. PubMed ID: 35588917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.
    Di Forti M; Quattrone D; Freeman TP; Tripoli G; Gayer-Anderson C; Quigley H; Rodriguez V; Jongsma HE; Ferraro L; La Cascia C; La Barbera D; Tarricone I; Berardi D; Szöke A; Arango C; Tortelli A; Velthorst E; Bernardo M; Del-Ben CM; Menezes PR; Selten JP; Jones PB; Kirkbride JB; Rutten BP; de Haan L; Sham PC; van Os J; Lewis CM; Lynskey M; Morgan C; Murray RM;
    Lancet Psychiatry; 2019 May; 6(5):427-436. PubMed ID: 30902669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.
    Bioque M; Mas S; Costanzo MC; Cabrera B; Lobo A; González-Pinto A; Rodriguez-Toscano E; Corripio I; Vieta E; Baeza I; Ibáñez Á; Fraile MG; Cuesta MJ; Mezquida G; Lafuente A; Bernardo M;
    Eur Neuropsychopharmacol; 2019 Jun; 29(6):786-794. PubMed ID: 31076188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the
    Fatjó-Vilas M; Soler J; Ibáñez MI; Moya-Higueras J; Ortet G; Guardiola-Ripoll M; Fañanás L; Arias B
    J Psychopharmacol; 2020 Sep; 34(9):990-998. PubMed ID: 32536252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.
    Colizzi M; Iyegbe C; Powell J; Ursini G; Porcelli A; Bonvino A; Taurisano P; Romano R; Masellis R; Blasi G; Morgan C; Aitchison K; Mondelli V; Luzi S; Kolliakou A; David A; Murray RM; Bertolino A; Di Forti M
    Schizophr Bull; 2015 Sep; 41(5):1171-82. PubMed ID: 25829376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction between the ZNF804A gene and cannabis use on the risk of psychosis in a non-clinical sample.
    Soler J; Arias B; Moya J; Ibáñez MI; Ortet G; Fañanás L; Fatjó-Vilas M
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():174-180. PubMed ID: 30118824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis and psychosis: have we found the missing links?
    Parakh P; Basu D
    Asian J Psychiatr; 2013 Aug; 6(4):281-7. PubMed ID: 23810133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis, COMT and psychotic experiences.
    Zammit S; Owen MJ; Evans J; Heron J; Lewis G
    Br J Psychiatry; 2011 Nov; 199(5):380-5. PubMed ID: 21947654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.
    Arendt M; Mortensen PB; Rosenberg R; Pedersen CB; Waltoft BL
    Arch Gen Psychiatry; 2008 Nov; 65(11):1269-74. PubMed ID: 18981338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic overlap between schizophrenia and bipolar disorder: a study with AKT1 gene variants and clinical phenotypes.
    Karege F; Méary A; Perroud N; Jamain S; Leboyer M; Ballmann E; Fernandez R; Malafosse A; Schürhoff F
    Schizophr Res; 2012 Mar; 135(1-3):8-14. PubMed ID: 22277669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val¹⁵⁸Met polymorphism.
    Vinkers CH; Van Gastel WA; Schubart CD; Van Eijk KR; Luykx JJ; Van Winkel R; Joëls M; Ophoff RA; Boks MP; ; Bruggeman R; Cahn W; de Haan L; Kahn RS; Meijer CJ; Myin-Germeys I; van Os J; Wiersma D
    Schizophr Res; 2013 Oct; 150(1):303-11. PubMed ID: 23954148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effects of AKT serine/threonine kinase 1 polymorphisms and environment on congenital heart disease risk: A case-control study.
    Zhao J; Zeng Z
    Medicine (Baltimore); 2020 Jun; 99(26):e20400. PubMed ID: 32590727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
    Quattrone D; Ferraro L; Tripoli G; La Cascia C; Quigley H; Quattrone A; Jongsma HE; Del Peschio S; Gatto G; ; Gayer-Anderson C; Jones PB; Kirkbride JB; La Barbera D; Tarricone I; Berardi D; Tosato S; Lasalvia A; Szöke A; Arango C; Bernardo M; Bobes J; Del Ben CM; Menezes PR; Llorca PM; Santos JL; Sanjuán J; Tortelli A; Velthorst E; de Haan L; Rutten BPF; Lynskey MT; Freeman TP; Sham PC; Cardno AG; Vassos E; van Os J; Morgan C; Reininghaus U; Lewis CM; Murray RM; Di Forti M
    Psychol Med; 2021 Jun; 51(8):1329-1337. PubMed ID: 32183927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.
    Di Forti M; Marconi A; Carra E; Fraietta S; Trotta A; Bonomo M; Bianconi F; Gardner-Sood P; O'Connor J; Russo M; Stilo SA; Marques TR; Mondelli V; Dazzan P; Pariante C; David AS; Gaughran F; Atakan Z; Iyegbe C; Powell J; Morgan C; Lynskey M; Murray RM
    Lancet Psychiatry; 2015 Mar; 2(3):233-8. PubMed ID: 26359901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.